

# **MEDI-CAPS LIMITED**

Regd. Office and works:  
Mhow-Neemuch Road, Sector 1,  
Pithampur - 454775, Distt. Dhar  
Madhya Pradesh, India

Ph:- +91-7292- 424242  
Fax:- 07292- 407387  
E mail:- [info@medicaps.com](mailto:info@medicaps.com)  
Web site:- [www.medicaps.com](http://www.medicaps.com)

CIN: L24232MP1983PLC002231

**MCL/SE/2019-20**

**30<sup>th</sup> July, 2019**

Online filing at: [www.listing.bseindia.com](http://www.listing.bseindia.com)

To  
The General Manager  
DCS-CRD  
BSE Ltd.  
Rotunda Building,  
P.J. Tower, Dalal Street, Fort  
MUMBAI - 400001

**BSE Code: 523144**

**Sub: Submission of the Standalone & Consolidated Un-Audited Quarterly Financial Results for the quarter ended 30<sup>th</sup> June, 2019 as per Regulation 33 of SEBI (LODR) Regulation, 2015.**

Dear Sir,

This is in continuation of our letter no. MCL/BM/SE/2019-20 dated 18/07/2019 regarding information for 2/2019-20 Board meeting for approval of the Standalone and Consolidated Un-Audited Quarterly Financial Results for the quarter ended 30<sup>th</sup> June, 2019:

We are pleased to inform that, Board of Directors at their meeting held on 30<sup>th</sup> July, 2019 has considered and approved the following which is also being submitted to you:

- (a) Unaudited Standalone and Consolidated Financial Results for the quarter 30<sup>th</sup> June, 2019; and
- (b) Limited Review Report by the Auditors for the Standalone and Consolidated for the quarter 30<sup>th</sup> June, 2019,


We are also in process of filing the aforesaid financial results in the XBRL format within the stipulated time and the same shall be hosted on the Website of the Company.

The above results will be published in Hindi (vernacular) and widely circulated English Newspaper.

You are requested to take on record the above said financial results for your reference and record.

Thanking You,  
Yours Faithfully,

For, **MEDI-CAPS LTD.**

  
**AYUSHI SILOT**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**  
Encl.: a/a



# RAWKA & ASSOCIATES

— CHARTERED ACCOUNTANTS —

412, Arcade Silver 56, 1, New Palasia, Indore - 1

☎ Off. : 2541132, Fax : 4215397, Mobile : 9039080380

E-mail : rawkaassociates@gmail.com, . cprawka@gmail.com

To,  
The Members,

We have reviewed the accompanying statement of unaudited financial results of **Medi-Caps Limited** for the period ended **30/06/2019**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Place:** Pithampur

**Date:** 30<sup>th</sup> July, 2019

**FOR, M/s Rawka & Associates**

Chartered Accountants

FRN: 021606C

UDIN:



**Venus Rawka**

Partner

M.N. 429040



Independent Auditor's Review Report On consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

## TO THE BOARD OF DIRECTORS OF Medi-Caps Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Medi-Caps Limited** and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiary for the quarter ended 30/06/2019 and for the period from 01/04/2019 to 30/06/2019 , being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30/06/2018 and the corresponding period from 01/04/2018 to 30/06/2018, as reported in these financial results have been approved by the Parent's Board of Directors.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.




We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its subsidiary Medgel Private Limited.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consolidated review report of its subsidiary, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. Our conclusion is not modified in respect of this matter.
7. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of Medgel Private Limited (subsidiary) which have not been reviewed/audited by their auditors, whose interim consolidated financial statements/ financial information/ financial results reflect total assets of Rs.10614.25 Lakhs as at 30.06.2019 and total revenue of Rs. 1615.47 Lakhs, total net profit/(loss) after tax of Rs. 63.87 Lakhs and total comprehensive income of Rs. 135.56 Lakhs for the quarter ended 30/06/2019, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter

Place: Indore  
Date: 30/07/2019

**For: Rawka & Associates**  
Chartered Accountants  
FRN: 021606C



**Venus Rawka**  
(Partner)  
M.No. 429040

# MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-424242, Fax: 07292-407387

Website: www.medicaps.com Email: investors@medicaps.com CIN: L24232MP1983PLC002231

STATEMENT OF STANDALONE & CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2019

(Rs.in Lakhs except EPS)

| Sr. No.      | Particulars  | STANDALONE                |                         |                           |                         | CONSOLIDATED              |                         |                           |                         |
|--------------|--|---------------------------|-------------------------|---------------------------|-------------------------|---------------------------|-------------------------|---------------------------|-------------------------|
|              |  | Quarter Ended             |                         | Year ended                |                         | Quarter Ended             |                         | Year ended                |                         |
|              |  | 30.06.2019<br>(Unaudited) | 31.03.2019<br>(Audited) | 30.06.2018<br>(Unaudited) | 31.03.2019<br>(Audited) | 30.06.2019<br>(Unaudited) | 31.03.2019<br>(Audited) | 30.06.2018<br>(Unaudited) | 31.03.2019<br>(Audited) |
| <b>I</b>     | <b>Income from operations</b>  |                           |                         |                           |                         |                           |                         |                           |                         |
|              | (a) Net sales  | 462.92                    | 529.04                  | 488.22                    | 2161.85                 | 1577.90                   | 1510.84                 | 786.21                    | 5178.29                 |
|              | (b) Other operating income   | 20.24                     | 34.93                   | 12.24                     | 87.10                   | 20.24                     | 34.93                   | 12.24                     | 213.76                  |
|              | <b>Total income from operation</b>   | <b>483.16</b>             | <b>563.96</b>           | <b>500.46</b>             | <b>2248.95</b>          | <b>1598.14</b>            | <b>1545.77</b>          | <b>798.45</b>             | <b>5392.05</b>          |
| <b>II</b>    | <b>Other Income</b>  | 0.00                      | 0.62                    | 0.48                      | 26.63                   | 17.33                     | 42.13                   | 65.78                     | 58.43                   |
| <b>III</b>   | <b>Total income (I+II)</b>   | <b>483.16</b>             | <b>564.58</b>           | <b>500.94</b>             | <b>2275.58</b>          | <b>1615.47</b>            | <b>1587.90</b>          | <b>864.23</b>             | <b>5450.48</b>          |
| <b>IV</b>    | <b>Expenses</b>  |                           |                         |                           |                         |                           |                         |                           |                         |
|              | a) Cost of material consumed   | 200.29                    | 266.10                  | 238.15                    | 1050.37                 | 900.60                    | 814.22                  | 487.44                    | 2632.48                 |
|              | b) Purchase of stock in trade  | 0.00                      | 4.54                    | 10.73                     | 15.26                   | 0.00                      | 4.54                    | 10.73                     | 15.26                   |
|              | c) Changes in inventories of finished goods, work-in-progress and stock-in-trade   | (4.54)                    | (37.09)                 | (51.69)                   | (51.81)                 | 16.66                     | (138.81)                | 20.27                     | (13.32)                 |
|              | d) Employee benefits expense   | 127.15                    | 140.36                  | 127.46                    | 518.93                  | 240.49                    | 292.41                  | 223.59                    | 956.06                  |
|              | e) Finance Charges   | 0.26                      | 0.30                    | 0.39                      | 1.36                    | 0.31                      | 0.31                    | 0.10                      | 1.80                    |
|              | f) Power Cost  | 81.16                     | 86.16                   | 85.86                     | 345.46                  | 113.02                    | 135.27                  | 106.56                    | 497.13                  |
|              | g) Depreciation and amortisation expense   | 9.06                      | 9.01                    | 8.67                      | 35.02                   | 45.83                     | 45.54                   | 45.44                     | 181.14                  |
|              | h) Other expenses  | 63.42                     | 84.48                   | 70.89                     | 290.23                  | 232.69                    | 207.97                  | 142.39                    | 629.59                  |
|              | <b>Total Expenses (IV)</b>   | <b>476.79</b>             | <b>553.86</b>           | <b>490.47</b>             | <b>2204.81</b>          | <b>1549.60</b>            | <b>1361.45</b>          | <b>1036.52</b>            | <b>4900.13</b>          |
| <b>V</b>     | <b>Profit / (Loss) before exceptional item &amp; tax (III-IV)</b>  | <b>6.37</b>               | <b>10.73</b>            | <b>10.47</b>              | <b>70.76</b>            | <b>65.87</b>              | <b>226.45</b>           | <b>(172.29)</b>           | <b>550.35</b>           |
| <b>VI</b>    | <b>Exceptional items</b>   | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    |
| <b>VII</b>   | <b>Profit/(Loss) before extra-ordinary items and tax (V-VI)</b>  | <b>6.37</b>               | <b>10.73</b>            | <b>10.47</b>              | <b>70.76</b>            | <b>65.87</b>              | <b>226.45</b>           | <b>(172.29)</b>           | <b>550.35</b>           |
| <b>VIII</b>  | <b>Extraordinary items</b>   | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    |
| <b>IX</b>    | <b>Profit/(Loss) after extra-ordinary items but before tax (VII-VIII)</b>  | <b>6.37</b>               | <b>10.73</b>            | <b>10.47</b>              | <b>70.76</b>            | <b>65.87</b>              | <b>226.45</b>           | <b>(172.29)</b>           | <b>550.35</b>           |
| <b>X</b>     | <b>Tax expense</b>   |                           |                         |                           |                         |                           |                         |                           |                         |
|              | a) Current Tax   | 2.00                      | 0.00                    | 3.00                      | 10.00                   | 2.00                      | 0.00                    | 3.00                      | 10.00                   |
|              | b) Deferred Tax  | 0.00                      | 1.65                    | 0.00                      | 1.65                    | 0.00                      | 1.65                    | 0.00                      | 1.65                    |
|              | <b>Total Tax Expenses</b>  | <b>2.00</b>               | <b>1.65</b>             | <b>3.00</b>               | <b>11.65</b>            | <b>2.00</b>               | <b>1.65</b>             | <b>3.00</b>               | <b>11.65</b>            |
| <b>XI</b>    | <b>Profit / (Loss) for the period from continuing operations (IX-X)</b>  | <b>4.37</b>               | <b>9.08</b>             | <b>7.47</b>               | <b>59.12</b>            | <b>63.87</b>              | <b>224.80</b>           | <b>(175.29)</b>           | <b>538.70</b>           |
| <b>XII</b>   | <b>Profit / (Loss) for the period from Discontinuing operations</b>  | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    |
| <b>XIII</b>  | <b>Tax expenses for Discontinuing operation</b>  | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    |
| <b>XIV</b>   | <b>Profit/(Loss) from discontinuing operations (after tax) (XII-XIII)</b>  | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    |
| <b>XV</b>    | <b>Profit / (Loss) for the period (XI+XIV)</b>   | <b>4.37</b>               | <b>9.08</b>             | <b>7.47</b>               | <b>59.12</b>            | <b>63.87</b>              | <b>224.80</b>           | <b>(175.29)</b>           | <b>538.70</b>           |
| <b>XVI</b>   | <b>Other Comprehensive Income:</b>   |                           |                         |                           |                         |                           |                         |                           |                         |
|              | A (i) items that will not be reclassified to P& L  | 101.71                    | -                       | -                         | -                       | 135.56                    | -                       | -                         | -                       |
|              | (ii) Income tax relating to items that will not be reclassified to Profit & loss   | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    |
|              | B (i) items that will be reclassified to P& L  | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    |
|              | (ii) Income tax relating to items that will be reclassified to Profit & loss   | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    |
| <b>XVII</b>  | <b>Total comprehensive income for the period (XV + XVI) ( Comprising Profit/(Loss) and Other Comprehensive Income for the period</b> | <b>106.08</b>             | <b>9.08</b>             | <b>7.47</b>               | <b>59.12</b>            | <b>199.43</b>             | <b>224.80</b>           | <b>(175.29)</b>           | <b>538.70</b>           |
| <b>XVIII</b> | <b>Paid up Equity Share Capital (Face Value of Rs. 10/- each)</b>  | 1247.00                   | 1247.00                 | 1247.00                   | 1247.00                 | 1247.00                   | 1247.00                 | 1247.00                   | 1247.00                 |
| <b>XIX</b>   | <b>Reserve excluding revaluation reserve as per balance sheet of previous accounting year</b>  | -                         | -                       | -                         | 5503.78                 |                           |                         |                           | 8313.35                 |
| <b>XX</b>    | <b>Earnings Per Share for continuing operations:</b>   |                           |                         |                           |                         |                           |                         |                           |                         |
|              | (a) Basic  | 0.85                      | 0.07                    | 0.06                      | 0.47                    | 1.60                      | 1.80                    | (1.41)                    | 4.32                    |
|              | (b) Diluted  | 0.85                      | 0.07                    | 0.06                      | 0.47                    | 1.60                      | 1.80                    | (1.41)                    | 4.32                    |
| <b>XXI</b>   | <b>Earnings Per Share for Dis-continued operations:</b>  |                           |                         |                           |                         |                           |                         |                           |                         |
|              | (a) Basic  | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    |
|              | (b) Diluted  | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    | 0.00                      | 0.00                    |
| <b>XXII</b>  | <b>Earnings Per Share for (Dis-continued and Continuing operations:)</b>   |                           |                         |                           |                         |                           |                         |                           |                         |
|              | (a) Basic  | 0.85                      | 0.07                    | 0.06                      | 0.47                    | 1.60                      | 1.80                    | (1.41)                    | 4.32                    |
|              | (b) Diluted  | 0.85                      | 0.07                    | 0.06                      | 0.47                    | 1.60                      | 1.80                    | (1.41)                    | 4.32                    |

**Notes:**

- The above results were reviewed by the Audit Committee and thereafter have been adopted by the Board at its meeting held on 30th July, 2019.
- The Company has adopted Companies (Indian Accounting Standards) Rules, 2015 (IND AS) from 01st April, 2017 and accordingly this financial results have been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 interim financial reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules made there under.
- The Company is operating in one segment.




4. Effective from 1st April, 2019, the company has adopted Indian Accounting Standards (IND AS) 116 "Leases" using the "Modified Prospective Approach". The adoption of the said IND AS did not have any impact on the retained earnings as at 1st April, 2019 and there was no material impact on financial results for the quarter ended on 30th June, 2019.
5. Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

Place : PITHAMPUR  
Date : 30/07/2019



For MEDI-CAPS LIMITED  
  
ALOK K. GARG  
MANAGING DIRECTOR  
DIN: 00274321